Peter de Blank, MD, MSCE
- Co-Medical Director, Brain Tumor Center
- Professor, UC Department of Pediatrics
- peter.deblank@cchmc.org
- Board Certified
About
Biography
Dr. de Blank graduated from the University of California, San Francisco School of Medicine with a concentration in Medical Education. He completed his residency in Pediatrics, and fellowships in Pediatric Hematology & Oncology and Pediatric Neuro-Oncology at the Children’s Hospital of Philadelphia. He completed a Masters of Science in Clinical Epidemiology and Biostatistics at the University of Pennsylvania during his fellowship training. After completing his training, he became a faculty member at University Hospitals Rainbow Babies & Children’s Hospital in Cleveland in 2012. In 2017, Dr. de Blank joined the faculty at Cincinnati Children’s Hospital Medical Center as a member of the Pediatric Neuro-Oncology program.
Dr. de Blank’s clinical and research interests include children with central nervous system tumors, neurofibromatosis type 1 (NF1), and NF1-related tumors. His research focuses on the investigation of tissue microstructure in pediatric brain tumors through non-invasive imaging techniques such as MR relaxometry and diffusion tensor imaging. The goal of his research is to develop early radiographic tumor biomarkers to characterize pediatric brain tumors and predict their functional consequences. Tumor imaging research may guide early intervention efforts and direct support for children with brain tumors in order to improve clinical outcomes in children with brain tumors.
Dr. de Blank has been elected by peers for inclusion in the Best Doctors in America List.
BA: Stanford University, Stanford, CA, 1997.
BS: Chemistry, Stanford University, Stanford, CA, 1997.
MA: Stanford University, Stanford, CA, 1997.
MD: Emphasis in Medical Education, University of California, San Francisco School of Medicine, San Francisco, CA, 2005.
MS: Clinical Epidemiology, University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA, 2011.
Intern: Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2005-2006.
Resident: Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2006-2008.
Fellow: Pediatric Hematology and Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2008-2011; Pediatric Neuro-Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2011-2012.
Interests
Pediatric neuro-oncology; neurofibromatosis type 1 (NF1); NF1-associated brain tumors
Services and Specialties
Cancer and Blood Diseases, Brain Tumor, Rasopathy, Neurofibromatosis
Interests
Cancer imaging; diffusion tensor imaging; MR relaxometry; magnetic resonance fingerprinting; developmental therapeutics
Research Areas
Cancer and Blood Diseases, Oncology
Locations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition. Neuro-Oncology. 2024; 26:1357-1366.
MDB-100. RETROSPECTIVE ANALYSIS OF CUMULATIVE DOSING OF CHEMOTHERAPY AGENTS AND THE EFFECT ON SURVIVAL IN PATIENTS WITH AVERAGE RISK MEDULLOBLASTOMA TREATED ON CHILDRENS ONCOLOGY GROUP STUDY ACNS0331. Neuro-Oncology. 2024; 26:0.
DIPG-17. DYSREGULATED PURINE METABOLISM IN A LETHAL CHILDHOOD BRAINSTEM TUMOR REVEALS NEW TREATMENT STRATEGIES WITH OLD DRUGS. Neuro-Oncology. 2024; 26:0.
NFS-21. DEMOGRAPHIC, CLINICAL AND IMAGING CHARACTERISTICS OF NEWLY DIAGNOSED OPTIC PATHWAY GLIOMAS ASSOCIATED WITH NF1: RESULTS FROM THE INTERNATIONAL MULTICENTER NF1-OPG NATURAL HISTORY STUDY. Neuro-Oncology. 2024; 26:0.
A Radiomic Approach for Evaluating Intra-Subgroup Heterogeneity in SHH and Group 4 Pediatric Medulloblastoma: A Preliminary Multi-Institutional Study. Cancers. 2024; 16.
MDB-42. RADIOMIC TEXTURAL AND MORPHOLOGICAL-BASED FEATURES TO RISK-STRATIFY PEDIATRIC MEDULLOBLASTOMA PATIENTS. Neuro-Oncology. 2024; 26:0.
MDB-40. DEFORMATION-HETEROGENEITY RADIOMIC MEASURES TO RISK-STRATIFY PEDIATRIC MEDULLOBLASTOMA PATIENTS: A PRELIMINARY ANALYSIS. Neuro-Oncology. 2024; 26:0.
NFS-08. CLINICAL AND MOLECULAR FEATURES OF HIGH-GRADE GLIOMA IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1: A PRELIMINARY ANALYSIS. Neuro-Oncology. 2024; 26:0.
MDB-86. ISOTRETINOIN HAS NO EFFECT ON EVENT FREE SURVIVAL ACROSS HIGH-RISK MEDULLOBLASTOMA MOLECULAR SUBGROUPS WHEN ADDED TO MAINTENANCE CHEMOTHERAPY: A SECONDARY ANALYSIS OF THE CHILDREN’S ONCOLOGY GROUP ACNS0332 DATA. Neuro-Oncology. 2024; 26:0.
TRLS-09. CONNECT1903: A PILOT AND SURGICAL STUDY OF LAROTRECTINIB FOR TREATMENT OF CHILDREN WITH NEWLY DIAGNOSED HGG WITH NTRK FUSION (NCT04655404). Neuro-Oncology. 2024; 26:0.
From the Blog
Study: Improved Chemotherapy and Surgery Eliminating Need for Radiation for Low-Grade Gliomas
Peter de Blank, MD, MSCE3/4/2024
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey